Challenges coexist with opportunities: development of a macrocyclic peptide PET radioligand for PD-L1.
作者信息
Huang Wenpeng, Son Mai Hong, Ha Le Ngoc, Kang Lei, Cai Weibo
机构信息
Department of Nuclear Medicine, Peking University First Hospital, No.8 Xishiku Str, Xicheng District, Beijing, 100034, China.
Department of Nuclear Medicine, Hospital 108, Hanoi, Vietnam.
出版信息
Eur J Nucl Med Mol Imaging. 2024 May;51(6):1574-1577. doi: 10.1007/s00259-024-06680-3.
Abstract
摘要
相似文献
1
Challenges coexist with opportunities: development of a macrocyclic peptide PET radioligand for PD-L1.挑战与机遇并存：开发用于程序性死亡受体配体1（PD-L1）的大环肽正电子发射断层扫描（PET）放射性配体。
Eur J Nucl Med Mol Imaging. 2024 May;51(6):1574-1577. doi: 10.1007/s00259-024-06680-3.
2
The discovery and evaluation of [F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement.发现和评估 [F]BMS-986229，一种新型大环肽 PET 放射性配体，用于测量 PD-L1 表达和体内 PD-L1 靶标结合。
Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):978-990. doi: 10.1007/s00259-023-06527-3. Epub 2023 Dec 5.
3
Evaluation of a Radiolabeled Macrocyclic Peptide as Potential PET Imaging Probe for PD-L1.评估一种放射性标记的大环肽作为 PD-L1 的潜在 PET 成像探针。
ChemMedChem. 2022 Jun 20;17(12):e202200091. doi: 10.1002/cmdc.202200091. Epub 2022 Apr 28.
4
Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.生物活性大环 PD-1/PD-L1 免疫检查点抑制剂。
Angew Chem Int Ed Engl. 2017 Oct 23;56(44):13732-13735. doi: 10.1002/anie.201707707. Epub 2017 Sep 26.
5
Synthesis and Biologic Evaluation of a Novel F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression.新型 F 标记的衔接蛋白的合成及生物学评价，作为 PD-L1 表达的 PET 放射性配体。
J Nucl Med. 2018 Mar;59(3):529-535. doi: 10.2967/jnumed.117.199596. Epub 2017 Oct 12.
6
Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis.一种 PD-1/PD-L1 免疫检查点轴的大环肽调节剂的结构特征。
Molecules. 2021 Aug 11;26(16):4848. doi: 10.3390/molecules26164848.
7
Process Development of a Macrocyclic Peptide Inhibitor of PD-L1.程序性死亡配体1（PD-L1）大环肽抑制剂的工艺开发
J Org Chem. 2024 May 17;89(10):6651-6663. doi: 10.1021/acs.joc.4c00430. Epub 2024 Apr 25.
8
PET imaging of PD-L1 with a small molecule radiotracer.使用小分子放射性示踪剂对程序性死亡受体配体1（PD-L1）进行正电子发射断层显像（PET）。
Eur J Nucl Med Mol Imaging. 2024 May;51(6):1578-1581. doi: 10.1007/s00259-024-06663-4.
9
A Novel Small Cyclic Peptide-Based Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors.一种新型基于小环状肽的 Ga 放射性示踪剂，用于正电子发射断层扫描成像肿瘤中 PD-L1 的表达。
Mol Pharm. 2022 Jan 3;19(1):138-147. doi: 10.1021/acs.molpharmaceut.1c00694. Epub 2021 Dec 15.
10
Development, Characterization, and Radiation Dosimetry Studies of F-BMS-986229, a F-Labeled PD-L1 Macrocyclic Peptide PET Tracer.F-BMS-986229 是一种 F 标记的 PD-L1 大环肽 PET 示踪剂，本研究对其进行了开发、表征和辐射剂量学研究。
Mol Imaging Biol. 2024 Apr;26(2):301-309. doi: 10.1007/s11307-023-01889-4. Epub 2023 Dec 20.
本文引用的文献
1
Development of small-molecular-based radiotracers for PET imaging of PD-L1 expression and guiding the PD-L1 therapeutics.开发基于小分子的放射性示踪剂，用于 PD-L1 表达的 PET 成像，并指导 PD-L1 治疗。
Eur J Nucl Med Mol Imaging. 2024 May;51(6):1582-1592. doi: 10.1007/s00259-024-06610-3. Epub 2024 Jan 22.
2
Clinical Application of ImmunoPET Targeting Checkpoint Inhibitors.免疫正电子发射断层显像靶向检查点抑制剂的临床应用
Cancers (Basel). 2023 Nov 30;15(23):5675. doi: 10.3390/cancers15235675.
3
The discovery and evaluation of [F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement.发现和评估 [F]BMS-986229，一种新型大环肽 PET 放射性配体，用于测量 PD-L1 表达和体内 PD-L1 靶标结合。
Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):978-990. doi: 10.1007/s00259-023-06527-3. Epub 2023 Dec 5.
4
Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD-L1 in Cancer Therapy.挑战与机遇并存：癌症治疗中 PD-L1 的空间异质性表达。
Adv Sci (Weinh). 2024 Jan;11(1):e2303175. doi: 10.1002/advs.202303175. Epub 2023 Nov 7.
5
Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.新型基于肽的放射性示踪剂用于检测 PD-L1 表达和指导癌症免疫治疗的研究进展。
Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):625-640. doi: 10.1007/s00259-023-06480-1. Epub 2023 Oct 25.
6
A novel [Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer.一种新型 [Zr]-抗 PD-1-PET-CT 用于评估肺癌对 PD-1/PD-L1 阻断的反应。
Front Immunol. 2023 Sep 28;14:1272570. doi: 10.3389/fimmu.2023.1272570. eCollection 2023.
7
[Ga]Ga-AUNP-12 PET imaging to assess the PD-L1 status in preclinical and first-in-human study.利用[镓]镓-金纳米颗粒-12正电子发射断层显像（PET）成像评估临床前和首次人体研究中的程序性死亡受体配体1（PD-L1）状态。
Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):369-379. doi: 10.1007/s00259-023-06447-2. Epub 2023 Sep 28.
8
An overview of current advances of PD-L1 targeting immuno-imaging in cancers.癌症中 PD-L1 靶向免疫成像的最新进展概述。
J Cancer Res Ther. 2023 Aug;19(4):866-875. doi: 10.4103/jcrt.jcrt_88_23.
9
PD-L1 - targeted magnetic fluorescent hybrid nanoparticles: Illuminating the path of image-guided cancer immunotherapy.程序性死亡受体配体1（PD-L1）靶向磁性荧光杂化纳米颗粒：照亮图像引导癌症免疫治疗之路。
Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2240-2243. doi: 10.1007/s00259-023-06202-7.
10
Preclinical and first-in-human evaluation of F-labeled D-peptide antagonist for PD-L1 status imaging with PET.用于 PD-L1 状态 PET 成像的 F 标记 D-肽拮抗剂的临床前和人体首次评估。
Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4312-4324. doi: 10.1007/s00259-022-05876-9. Epub 2022 Jul 14.
Zotero 插件